Neurocrine Biosciences (NASDAQ: NBIX) generated $959 million in revenue in Q2 2026, representing an increase of 39% year over year. Its flagship drug, Ingrezza, continues to deliver double-digit percentage sales growth, while two newer treatments help the company expand beyond its original neurological disease franchise. Neurocrine is also approaching several important clinical milestones, including late-stage trial results for experimental treatments targeting depression and schizophrenia. By 2031, I expect Neurocrine to be a substantially larger pharmaceutical company, potentially generating more than $6 billion in annual revenue. Whether its stock follows that growth, however, will depend on the success of its newer drugs and how much investors are willing to pay for its earnings. If you're unfamiliar, Ingrezza treats tardive dyskinesia, a neurological condition that causes involuntary movements, often associated with long-term use of certain psychiatric medications. It's also approved to treat chorea (involuntary muscle movements) associated with Huntington's disease.
CryptoAlerta — análise de criptomoedas e mercado em tempo real